FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search


Full Text:


to conduct analysis of basal-bolus insulin detemir/aspart in comparison with the NPH/human insulin for the treatment of patients with diabetes mellitus type 1 in Russia. We evaluate results of PREDICTIVE study using pharmacoeconomic analyses: «cost – effectiveness,» «cost – utility» and « budget impact». Analysis included the most widely known insulins: Protaphane®, Actrapid®, NovoRapid® and Levemir® . The period of analysis was 1 year. Additional costs for insulin transition (Protaphane® /Actrapid® to Levemir® /NovoRapid®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles. The reduced frequency of severe hypoglycemia (Levemir® /NovoRapid®) con

About the Authors

E. E. Arinina
Laboratory of pharmacoeconomic researches, FirstMoscowStateMedicalUniversity named after I.M. Sechenov
Russian Federation

M. A. Rashyd
City clinical hospital № 55 Department of healthcare, Moscow, Russian Federation
Russian Federation


1. Дедов И.И. Лекарственное обеспечение больных сахарным диабетом в непростых условиях. Фармацевтический вестник. 2009; 10 (542): 8-9.

2. Мкртумян А.М., Оранская А.Н. Аналоги инсулина в клинической практике.

3. Официальный сайт Минздравcоцразвития РФ. URL:

4. Приказ Министерства здравоохранения и социального развития РФ от 11 сентября 2007 г. №582 «Об утверждении стандарта медицинской помощи больным с инсулинзависимым сахарным диабетом»

5. Ягудина Р.И., Куликов А.Ю., Комаров И.А. Методология проведения анализа «затрат» при проведении фармакоэкономических исследований. Фармакоэкономика. 2011; 3: 3-6.

6. Ягудина Р.И., Куликов А.Ю., Литвиненко М.М. QALY: история, методология и будущее метода. Фармакоэкономика. 2010; 1:7-11.

7. Ягудина Р.И., Куликов А.Ю. Теоретические основы фармакоэкономического метода: анализ «влияния на бюджет». Фармакоэкономика. 2011; 2: 9-12

8. Ягудина Р.И., Куликов А.Ю., Аринина Е.Е. Фармакоэкономика сахарного диабета второго типа. М. 2011; 352с.

9. Bjork S. The cost of diabetes and diabetes care. Diabetes Res. Clin. Pract. 2001; 54 (1): 13-18.

10. Dornhorst A., Luddeke H-J., Honka M., Ackermann R.W.,Merilainen M., Gallwitz B., Sreenan S. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. CurrentMedicalRe searchandOpinion. 2008; 24 (2): 369-376.

11. Hermansen K., Fontaine P., Kukolja K.K., Peterkova V., Leth G., GallM.A. Insulin analogues (insulin detemir and insulin aspart) versustraditional human insulins (NPH insulin and regular human insulin)in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004; 47: 622-9.

12. Heller S.R., Colagiuri S., Vaaler S., Wolffenbuttel B.H.R., Koelendorf K.,Friberg al. Hypoglycaemia with insulin aspart: a double-blind,randomised, crossover trial in subjects with Type 1 diabetes.Diabet.Med. 2004; 21: 769-75.

13. Howey D.C., Bowsher R.R., Brunelle R.L. et al. [Lys(B28), Pro(B29)]-humaninsulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.

14. Home P.D., Lindholm A., Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet.Med. 2000; 17: 762-70.

15. Home P.D., Hallgren P., Usadel K.H., Sane T., Faber J., Grill al. Premealinsulin aspart compared with pre-meal soluble human insulinin type 1 diabetes. Diabetes Res.Clin.Pract. 2005.

16. JDFI: Current status, Future Directions. Report of the Juvenile DiabetesFoundation International World Conference on Diabetes Research. Monaco. 1985.

17. Raskin P., Guthrie R.A., Leiter L., Riis A., Jovanovic L. Use of insulinaspart, a fast-acting insulin analog, as the mealtime insulin in themanagement of patients with type 1 diabetes. Diabetes Care. 2000; 23 (5): 583-8.

18. Raslova K., Bogoev M., Raz I., Leth G., Gall M-A., Hancu M. Insulindetemir and insulin aspart: a promising basal-bolus regimen fortype 2 diabetes. Diabetes Res. Clin. Pract. 2004; 66: 193-201.

19. Setter S.M., Corbett C.F., Campbell R.K. et al. Insulin aspart: a new rapid-actinginsulin analog. Ann. Pharmacother. 2000; 34: 1423-1431.

20. Siebenhofer A., Plank J., Berghold A. et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews. 2006; 2. Art. No.: CD003287.

21. The DCCT Research Group. The effect of intensive treatmentof diabetes on the development and progression of longtermcomplications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329: 977-86.

22. The UK Prospective Diabetes Study Group. Intensive bloodglucosecontrol with sulphonylureas or insulin compared withconventional treatment and risk of complications in patientswith type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.

23. Torlone E., Fanelli C., Rambotti A.M. et al. Pharmacokinetics, pharmacodynamicsand glucose counter-regulation following subcutaneous injection of themonomeric insulin analogue [Lys (B28), Pro (B29)] in IDDM. Diabetologia. 1994; 37: 713-720.

24. Vora J.P., Ibrahim H.A., Bakris G.L. Responding to the challengeof diabetic nephropathy: the historic evolution of detection, prevention and management. J. Hum. Hypertens. 2000; 14: 667-85.


For citations:

Arinina E.E., Rashyd M.A. CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2012;5(3):41-46. (In Russ.)

Views: 704

ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)